Undisclosed CCR6 inhibitor / Arcus Biosciences - LARVOL DELTA

Immunology Portfolio (Businesswire) - "Additional Targets: Arcus is advancing additional programs across its immunology portfolio. Arcus’s programs for a small-molecule CCR6 antagonist for psoriasis and inflammatory bowel disease, a STAT6 small molecule program for atopic dermatitis and asthma, a CD89 monoclonal antibody program for the treatment of rheumatoid arthritis, and a CD40L small molecule program for the treatment of multiple sclerosis and systemic lupus erythematosus, are each expected to deliver IND-ready candidates by the end of 2027."

Pipeline update • Asthma • Atopic Dermatitis • Immunology • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis • Systemic Lupus Erythematosus

Arcus..discovery and preclinical programs disclosed today provide multiple opportunities to advance into the clinic in 2026. (Arcus Biosciences Press Release) - "Potential new drug candidates include: MRGPRX2 small-molecule inhibitor, a potential treatment for atopic dermatitis and chronic spontaneous urticaria; TNF-a (TNFR1) small-molecule inhibitor, a potential treatment for rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (such as ulcerative colitis); CCR6 small-molecule inhibitor, a potential treatment for psoriasis; CD89 monoclonal antibody, a potential treatment for RA; CD40L small-molecule inhibitor, a potential treatment for multiple sclerosis and systemic lupus erythematosus"

New molecule • Atopic Dermatitis • Chronic Spontaneous Urticaria • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis • Systemic Lupus Erythematosus • Ulcerative Colitis